RJFSA
PCSA icon

Raymond James Financial Services Advisors’s Processa Pharmaceuticals PCSA Stock Holding History

Raymond James Financial Services Advisors’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-98
Closed -$24.5K – 3329
2023
Q1 		$24.5K Hold
98
– – ﹤0.01% 3168
2022
Q4 		$53.8K Buy
+98
New +$94.7K ﹤0.01% 3082

Other funds holding PCSA

Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CBA
Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Raymond James Financial Services Advisors's PCSA Position: Q2 2023 in Review

Raymond James Financial Services Advisors sold out of Processa Pharmaceuticals (PCSA) in Q2 2023, closing a stake of 98 shares — an estimated $24.5K sold.

Raymond James Financial Services Advisors first reported a position in PCSA in Q4 2022 and held it in 2 quarters. The position peaked at $53.8K in Q4 2022. 18 funds tracked by Wall St. Rank hold PCSA as of Q2 2023.

  • Raymond James Financial Services Advisors reported no remaining Processa Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 98 Processa Pharmaceuticals shares in Q2 2023, an estimated $24.5K.
  • Raymond James Financial Services Advisors first reported a position in Processa Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Raymond James Financial Services Advisors's Processa Pharmaceuticals position peaked at $53.8K in Q4 2022.
  • 18 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q2 2023.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2023, filed 25 Jul 2023.